Bioisosteric replacement based on 1,2,4-oxadiazoles in the discovery of 1H-indazole-bearing neuroprotective MAO B inhibitors.

[1]  A. Linusson,et al.  Probing Fluorinated Motifs onto Dual AChE-MAO B Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Early-ADME Studies. , 2022, Journal of medicinal chemistry.

[2]  F. Ekström,et al.  Dual Reversible Coumarin Inhibitors Mutually Bound to Monoamine Oxidase B and Acetylcholinesterase Crystal Structures , 2022, ACS medicinal chemistry letters.

[3]  Giuseppe Felice Mangiatordi,et al.  Structure-Based Prediction of hERG-Related Cardiotoxicity: A Benchmark Study , 2021, J. Chem. Inf. Model..

[4]  Gregory A Ross,et al.  OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space. , 2021, Journal of chemical theory and computation.

[5]  G. Zengin,et al.  Role of Monoamine Oxidase Activity in Alzheimer’s Disease: An Insight into the Therapeutic Potential of Inhibitors , 2021, Molecules.

[6]  Shoaib Manzoor,et al.  A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review. , 2020, European journal of medicinal chemistry.

[7]  M. Saviano,et al.  Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease , 2020, Frontiers in Chemistry.

[8]  A. Mattevi,et al.  Rational Redesign of Monoamine Oxidase A into a Dehydrogenase to Probe ROS in Cardiac Aging , 2020, ACS chemical biology.

[9]  B. Salehi,et al.  Therapeutic Potential of Quercetin: New Insights and Perspectives for Human Health , 2020, ACS omega.

[10]  C. Datta,et al.  Role of Monoamine Oxidase A (MAO-A) in Cardiac Aging , 2020 .

[11]  Janez Konc,et al.  Stereoselective Activity of 1-Propargyl-4-styrylpiperidine-like Analogues That Can Discriminate between Monoamine Oxidase Isoforms A and B , 2020, Journal of medicinal chemistry.

[12]  S. Carradori,et al.  Novel approaches to the discovery of selective human monoamine oxidase-B inhibitors: is there room for improvement? , 2019, Expert opinion on drug discovery.

[13]  Ashwini M. Londhe,et al.  Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease , 2019, Science Advances.

[14]  Allen F. Brooks,et al.  Classics in Neuroimaging: Development of PET Tracers for Imaging Monoamine Oxidases. , 2019, ACS chemical neuroscience.

[15]  E. Uriarte,et al.  Quercetin and Related Chromenone Derivatives as Monoamine Oxidase Inhibitors: Targeting Neurological and Mental Disorders , 2019, Molecules.

[16]  R. Iacobazzi,et al.  Investigating alkyl nitrates as nitric oxide releasing precursors of multitarget acetylcholinesterase-monoamine oxidase B inhibitors. , 2019, European journal of medicinal chemistry.

[17]  J. Shih.  Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy , 2018, Journal of Neural Transmission.

[18]  Chun-Peng Liao,et al.  Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate , 2018, Oncogene.

[19]  S. Carradori,et al.  MAO inhibitors and their wider applications: a patent review , 2018, Expert opinion on therapeutic patents.

[20]  O. Nicolotti,et al.  Mannich base approach to 5‐methoxyisatin 3‐(4‐isopropylphenyl)hydrazone: A water‐soluble prodrug for a multitarget inhibition of cholinesterases, beta‐amyloid fibrillization and oligomer‐induced cytotoxicity , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[21]  Lirong Wang,et al.  ProSelection: A Novel Algorithm to Select Proper Protein Structure Subsets for in Silico Target Identification and Drug Discovery Research , 2017, J. Chem. Inf. Model..

[22]  M. Catto,et al.  Discovery of Potent Dual Binding Site Acetylcholinesterase Inhibitors via Homo‐ and Heterodimerization of Coumarin‐Based Moieties , 2017, ChemMedChem.

[23]  B. Winblad,et al.  Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels , 2017, Alzheimer's Research & Therapy.

[24]  G. Lattanzi,et al.  A rational approach to elucidate human monoamine oxidase molecular selectivity , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[25]  Lydia Siragusa,et al.  Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents. , 2016, Journal of medicinal chemistry.

[26]  Sheetal,et al.  Recent developments on the structure–activity relationship studies of MAO inhibitors and their role in different neurological disorders , 2016 .

[27]  S. Genheden,et al.  The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.

[28]  Meryem Köse,et al.  8‐Benzyltetrahydropyrazino[2,1‐f]purinediones: Water‐Soluble Tricyclic Xanthine Derivatives as Multitarget Drugs for Neurodegenerative Diseases , 2014, ChemMedChem.

[29]  C. Müller,et al.  Indazole- and indole-5-carboxamides: selective and reversible monoamine oxidase B inhibitors with subnanomolar potency. , 2014, Journal of medicinal chemistry.

[30]  H. Sies.  Role of Metabolic H2O2 Generation , 2014, The Journal of Biological Chemistry.

[31]  O. Nicolotti,et al.  Fine molecular tuning at position 4 of 2H-chromen-2-one derivatives in the search of potent and selective monoamine oxidase B inhibitors. , 2013, European journal of medicinal chemistry.

[32]  R. Ramsay.  Inhibitor design for monoamine oxidases. , 2013, Current pharmaceutical design.

[33]  Walter Cabri,et al.  Synthesis of (E)-8-(3-chlorostyryl)caffeine analogues leading to 9-deazaxanthine derivatives as dual A(2A) antagonists/MAO-B inhibitors. , 2013, Journal of medicinal chemistry.

[34]  C. Saal,et al.  Optimizing solubility: kinetic versus thermodynamic solubility temptations and risks. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[35]  Andrea Mattevi,et al.  Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs. , 2012, ACS medicinal chemistry letters.

[36]  A. Mattevi,et al.  The ‘gating’ residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition , 2011, The FEBS journal.

[37]  K. Fujimori,et al.  Protective effects of quercetin against hydrogen peroxide-induced apoptosis in human neuronal SH-SY5Y cells , 2011, Neuroscience Letters.

[38]  J. P. Petzer,et al.  Inhibition of monoamine oxidase by indole and benzofuran derivatives. , 2010, European journal of medicinal chemistry.

[39]  C. Caccia,et al.  Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B i , 2009, Journal of medicinal chemistry.

[40]  F. Forneris,et al.  ThermoFAD, a Thermofluor®‐adapted flavin ad hoc detection system for protein folding and ligand binding , 2009, The FEBS journal.

[41]  E. Yamashita,et al.  Structure of human monoamine oxidase A at 2.2-Å resolution: The control of opening the entry for substrates/inhibitors , 2008, Proceedings of the National Academy of Sciences.

[42]  R. Lea,et al.  Monoamine oxidase and tobacco dependence. , 2007, Neurotoxicology.

[43]  Keith F. Tipton,et al.  The therapeutic potential of monoamine oxidase inhibitors , 2006, Nature Reviews Neuroscience.

[44]  Andrea Mattevi,et al.  Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Andrea Mattevi,et al.  Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Enzo Agostinelli,et al.  Simple, potent, and selective pyrrole inhibitors of monoamine oxidase types A and B. , 2003, Journal of medicinal chemistry.

[47]  K. Castagnoli,et al.  Synthesis and biological evaluation of MAO-A selective 1,4-disubstituted-1,2,3,6-tetrahydropyridinyl substrates. , 2002, Bioorganic & medicinal chemistry.

[48]  R. Copeland.  Tight Binding Inhibitors , 2002 .

[49]  R. Friesner,et al.  Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides† , 2001 .

[50]  D. Edmondson,et al.  High-level expression of human liver monoamine oxidase B in Pichia pastoris. , 2000, Protein expression and purification.

[51]  J. Shih,et al.  Monoamine oxidase: from genes to behavior. , 1999, Annual review of neuroscience.

[52]  V. Chan‐Palay,et al.  Increased monoamine oxidase b activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography , 1994, Neuroscience.

[53]  M. Berridge,et al.  Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. , 1993, Archives of biochemistry and biophysics.

[54]  K. Tipton,et al.  Interactions of monoamine oxidase with substrates and inhibitors , 1989, Medicinal research reviews.

[55]  W. Haefely,et al.  On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. , 1988, Journal of neural transmission. Supplementum.

[56]  E. Zeller,et al.  In vivo Inhibition of Liver and Brain Monoamine Oxidase by 1-Isonicotinyl-2-Isopropyl Hydrazine.∗ , 1952, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.